Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoRecormon once-weekly versus thrice-weekly dosing in chemotherapy-associated anemia in metastatic solid tumors
2006-002119-28Phase 3Terminated
- Sponsor
- Roche
- Start
- Jun 2006
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epoetin beta in anaemia (2 arms), sponsored by Roche. Primary endpoints: Hemoglobin area under the curve from week 5 to week 12 and Target hemoglobin response. Started Jun 2006; status: terminated.
02
Drugs
epoetin beta
03
Conditions
anaemia
Beyond the preview
Go deeper on 2006-002119-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002119-28.